Tarceva Off-Label Marketing Caused 'Earlier' Death, DOJ Alleged
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche and OSI Pharmaceuticals to pay $67m to resolve claims they misrepresented Tarceva effectiveness, diverting patients from first-line treatments and causing them to "die earlier and faster;" in other late-week legal developments, Salix settles kickback claims and former sales reps seemingly from Insys are arrested for fentanyl kickbacks.
You may also be interested in...
Insys ‘Reimbursement Unit’ Fraudulently Boosted Fentanyl Rxs, DOJ Charges
Six former Insys executives and managers arrested on changes of misleading insurers and pharmacy benefit managers into authorizing payments for Subsys sublingual fentanyl pain medicine.
Off-Label Compendia Weaknesses Illustrated By Tarceva Evidence Gaps
Compendia are often critical to reimbursement for oncology sponsors, but University of North Carolina researchers argue in JAMA the system needs to be revamped.
Pharma Deals With The DOJ
A look at the settlement agreements pharma companies have struck with the Department of Justice in the last three years; the size of the deals has declined dramatically since 2012.